| Bioactivity | Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1]. |
| Invitro | BI-505（1 ng/mL-1000 μg/mL）剂量依赖性地诱导表达 ICAM-1 的 Ramos、Raji 和 Daudi 淋巴瘤细胞的程序性细胞死亡 (PCD)[1]。 |
| In Vivo | Bersanlimab（BI-505；20 mg/kg；腹腔注射；每周两次；持续 21 天）显着减少肿瘤生长并延长动物存活期[1]。 Animal Model: |
| Name | Bersanlimab |
| CAS | 1987854-08-9 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Niina Veitonmäki, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. |